NCI Considering Adoption Of NIGMS Guidelines To Limit Growth Of Renewals, Ensure New Grants
In Brief: Three Patients Evaluated For Gene Therapy; Revised Program Instructions Available
Joseph Cullen, Cancer Prevention Leader, Dead At 54
‘Major Discover’ At FCRDC Is NF1 Gene, Report Says
DCT Advisors Reject MRS Concept, Approve RDOG Expansion
DCT Board Approves Drug Development Recompetition
Trending Stories
- Maura Gillison, who identified the role of HPV in head and neck cancer, changing the standard of care, dies at 61
- Prediction markets now allow betting on clinical trial results, FDA decisions
It’s a high-risk bet: Insider trading, equipoise, integrity of research, public trust are at stake - Trump plans a 200% tariff on imported generic drugs by 2029, raising fears of cancer drug shortages
“There is a reason why generics have been exempt from all the tariffs until now,” Brookings economist warns - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Retraction is not refutation: Why chrono-immunotherapy still deserves scientific investigation
- FDA’s OCE publishes three final guidances to increase clinical trial enrollment









